Chinese Procedure Numbers for Orthopedic Biomaterials 2016 – MedPro

Chinese Procedure Numbers for Orthopedic Biomaterials 2016 – MedPro


Bone graft substitutes are designed to fill bone voids, which eliminates the need for autograft harvesting of the patient’s own bone. Viscosupplementation products are injected directly into the affected knee joint to relieve pain caused by osteoarthritis. Growth factors are naturally occurring molecules in the body that mediate various cellular functions.

  • Year: 2016
  • Scope: 2012-2022
  • Region: China
  • Published Date: 02/01/2016
  • Pages: 37
  • Type: MedPro

Segments Covered in this Orthopedic Biomaterials Procedure Volume Research

This market study focuses specifically on the volume of procedures in the orthopedic biomaterials market. It includes analysis of procedures in the following segments:

  • Autograft Procedures
  • Allograft Procedures
  • DBM Procedures
  • Synthetic Procedures
  • Cervical Spine Procedures
  • Thoracolumbar Spine Procedures
  • Trauma Procedures
  • Bone Tumor Procedures
  • Hip Procedures
  • Knee Procedures
  • Foot/Ankle Procedures
  • CMF Procedures
  • Hyaluronic Acid Viscosupplementation Procedures

This data is then displayed over the forecast period, 2012-2022, outlining the exact growth rates for procedures in these segments. If you’re interested in seeing the trends in procedures to formulate your market sizing and forecasts this is the most accurate and most affordable way to do it.

About Procedure Volume Research (MedPro)

Our analysts meticulously research for 3 to 4 months to put together a suite of reports (MedSuite), which is a comprehensive analysis on a group of healthcare markets. A MedPro is one portion of that analysis that outlines only the procedure volumes and forecasts for each market in that suite of reports.

This procedural analysis is incorporated in our market size analysis and forecasting which are available when purchasing a MedSuite, MedView or MedCore. For a deeper description on these product types click here or contact us to have a product consultant help you find the data you need.

Where Do We Get Orthopedic Biomaterials Procedure Data?

Our team of analysts has proprietary data that we’ve been collecting for over a decade as well as government and private databases like that from CMS and hospital records. By looking at multiple sources we are able to triangulate on orthopedic biomaterials procedure volumes that influence and coincide with our overall market sizing.

Trends Affecting the Orthopedic Biomaterials Market

The orthopedic biomaterials market in China grew 6% in 2015, compared to 16% realized in 2013. The slowdown was due to both slower growth in procedures and decreasing ASP. Going forward the overall market is expected to grow at a 10.6% CAGR, noticeably slower than in the past mainly due to drastic decline in the ASP across all segments.

The fastest growing segment in 2015 was BGS realizing an increase of 8.3%, which is down from 2013 when it grew 12%. While facing the same challenges as the hyaluronic acid segment in terms of slower growth in procedures and declining ASP, this segment appears to be more stable as the large portion of it consists of allograft sub-segment that does not see rapid decline in procedures and ASP.

Questions This Report will Help You Answer

  • What is affecting the volume of procedures in China?
  • How many procedures were done in 2015?
  • How many procedures were done historically?
  • How many procedures can we expect in 2022 and what is the growth trend?

The "Chinese Market Report Suite for Orthopedic Biomaterials 2016 - MedSuite" includes analysis on the following companies currently active in this market:
Allgens Medical
Biolu Biomaterials
Bloomage Freda Biopharm
Datsing Biotech
DePuy Synthes
Guona Keji
Hanghzhou Gallop
Harbin Gloria Pharmaceutical
Jinxingda Company (Tianjin)
Kunming Baker Norton
Kunming Baker Norton
Meiji Seika
Osteolink Biomaterials
Rebone Biomaterials
Shanghai Anjiu Biotechnology
Shanghai HaoHai
Shanghai Jingfeng Pharmaceutical
Shanxi OsteoRad Biomaterial
Wright Medical
Xin Kang Chen

*Not all companies are currently active in every segment or sub-report from this suite. For more details contact an iData Research Product Advisor.

Our reports follow an in-depth 9-step methodology which focuses on the following research systems:

  • Original primary research that consists of the most up-to-date market data
  • Strong foundation of quantitative and qualitative research
  • Focused on the needs and strategic challenges of the industry participants

Step 1: Project Initiation & Team Selection During this preliminary investigation, all staff members involved in the industry discusses the topic in detail.

Step 2: Prepare Data Systems and Perform Secondary Research The first task of the research team is to prepare for the data collection process: Filing systems and relational databases are developed as needed.

Step 3: Preparation for Interviews & Questionnaire Design The core of all iData research reports is primary market research. Interviews with industry insiders represent the single most reliable way to obtain accurate, current data about market conditions, trends, threats and opportunities.

Step 4: Performing Primary Research At this stage, interviews are performed using contacts and information acquired in the secondary research phase.

Step 5: Research Analysis: Establishing Baseline Estimates Following the completion of the primary research phase, the collected information must be synthesized into an accurate view of the market status. The most important question is the current state of the market.

Step 6: Market Forecast and Analysis iData Research uses a proprietary method to combine statistical data and opinions of industry experts to forecast future market values.

Step 7: Identify Strategic Opportunities iData analysts identify in broad terms why some companies are gaining or losing share within a given market segment.

Step 8: Final Review and Market Release An integral part of the iData research methodology is a built-in philosophy of quality control and continuing improvement is integral to the iData philosophy.

Step 9: Customer Feedback and Market Monitoring iData philosophy of continuous improvement requires that reports and consulting projects be monitored after release for customer feedback and market accuracy.

Click Here to Read More About Our Methodology

Not Exactly What You Need?

Subscribe to MedTech Market News - Get exclusive analyst articles, monthly newsletters and iData offers